Neuphoria Therapeutics Inc(NEUP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.19 | Insider Own | 5.02% | Shs Outstand | 5.4M | Perf Week | -11.34% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | -1.23% | Insider Trans | - | Shs Float | 5.1M | Perf Month | -13.11% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 41.51% | Short Float | 0.13% | Perf Quarter | -22.39% |
| Income | -0.01B | P/S | 14.1 | EPS this Y | 40.29% | Inst Trans | 5.57% | Short Ratio | 0.2 | Perf Half Y | -41.57% |
| Sales | 0.00B | P/B | 0.67 | EPS next 5Y | - | ROA | - | Short Interest | 0.01M | Perf YTD | -21.39% |
| Book/sh | 4.55 | P/C | 0.83 | EPS past 3/5Y | -196.42% -98.3% | ROE | - | 52W High | -44.85% ($5.53) | Perf Year | -30.68% |
| Cash/sh | 3.67 | P/FCF | - | Sales past 3/5Y | - | ROIC | -54.68% | 52W Low | 0.59% ($3.03) | Perf 3Y | -89.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 79.08% | Gross Margin | 43.54% | Volatility(W/M) | 4.18% 3.62% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -2.85 | Sales Y/Y TTM | - | Oper. Margin | -835.53% | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 27.85 | EPS Q/Q | -113.83% | Profit Margin | -1145.66% | RSI (14) | 25.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 27.85 | Sales Q/Q | -92.17% | SMA20 | -8.86% ($3.35) | Beta | 0.75 | Target Price | $7 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -14.69% ($3.58) | Rel Volume | 2.2 | Prev Close | $3.06 |
| Employees | 1 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -26.73% ($4.16) | Avg Volume(3M) | 0.03M | Price | $3.05 |
| IPO | 2021/12/16 | Option/Short | No/Yes | Trades | 204 | Volume | 70,253 | Change | -0.33% |
🧠 Neuphoria Therapeutics () is a clinical-stage biotech developing oral anti-anxiety and neuropsychiatric therapies that target the α7 nicotinic receptor. Its lead candidate, BNC210, suffered a setback when it failed to meet the primary endpoint in the Phase 3 social anxiety disorder (SAD) trial, but the company is regrouping around the Phase 2b SYMPHONY trial in post-traumatic stress disorder (PTSD) and its Alzheimer's PAM partnership (MK-1167) with Merck (MRK), making it a small-cap neuroscience biotech play.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded more than usual. That is 220% of its average volume.
NEUP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +40.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,410. Peers typically go for $1,010. Compared with its own 1-year average, it is 49% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -90.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 41.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #473 of 597 in the industry
Based on market cap of $17M.
JSPR#471 Jasper Therapeutics Inc $17M PER - 
RADX#472 Radiopharm Theranostics Ltd ADR $17M PER - NEUP#473 Neuphoria Therapeutics Inc $17M PER - 
MRKR#474 Marker Therapeutics Inc $16M PER - 
AEON#475 AEON Biopharma Inc $16M PER - 
FAQ
What kind of company is NEUP?
NEUP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NEUP?
The market cap of NEUP is approximately $17M, ranking 5,268 within its sector.
What is the 52-week high and low for NEUP?
NEUP has recorded a 52-week high of $5.53 and a low of $3.03.
